Botanical Cost of Quality: An Economic Framework for Botanical Price Floors and Adulteration Prevention

Blake Ebersole¹, Trish Flaster²
¹NaturPro Scientific / Ethical Sourcing Review
²Botanical Liaisons / Ethical Sourcing Review

Abstract

Botanical ingredients used in foods, dietary supplements, and pharmaceutical products are uniquely vulnerable to economically motivated adulteration due to long, opaque supply chains, biological variability, and weak alignment between price and quality signals. 

Despite extensive documentation of adulteration in medicinal plants, the industry lacks an economic framework for identifying when a botanical price is implausibly low relative to the true cost of quality. 

This review introduces the Botanical Cost of Quality (BCOQ) framework, adapted from classical Cost of Quality (COQ) theory, as a tool for establishing economically defensible price floors for botanical commodities. 

Drawing on farm-level cost modeling, post-harvest handling, processing, testing, and compliance costs, w e synthesize published research demonstrating how ignoring these costs creates incentives for substitution, dilution, fraud, or otherwise sub-potent botanical products.

We further review documented adulteration case studies where application of a BCOQ-based price floor would likely have prevented fraudulent procurement. Adoption of BCOQ principles can improve supply-chain transparency, protect farmers, and reduce public-health risk by aligning purchasing decisions with the true economics of botanical quality.

Keywords: botanical adulteration; cost of quality; medicinal plants; supply chain economics; price floors; dietary supplements

1. Introduction

Medicinal plants form the backbone of traditional medicine systems and contribute substantially to modern food, supplement, and pharmaceutical industries. Global trade in botanicals exceeds $100 billion annually. Yet pricing mechanisms remain poorly aligned with product quality, supply chain dynamics, agricultural constraints, economic sustainability, and regulatory compliance.

Unlike industrial commodities, medicinal botanical ingredients used in foods and supplements vary widely in phytochemical composition, harvest practices and processing requirements. However, market prices for disparate products often converge toward a single price, based on “lowest-quality product” pricing. This creates economic pressure that incentivizes adulteration, particularly when authentic material cannot be produced profitably at prevailing prices.

This review applies the Botanical Cost of Quality (BCOQ) framework—an adaptation of classical COQ theory—to these botanical supply chains. Here, we apply farm-level economics and downstream quality costs to establish a model for calculating defensible price floors for a given botanical product.

This is an excerpt to a review paper now in peer-review prior to publication. Contact us to get involved in the BCOQ Project.

Posted on PricePlow on May 21, 2026 — The supplement industry is pushing back. In May 2026, a group of long-tenured ashwagandha producers and regulatory experts launched the Ashwagandha Standards Alliance (ASA), a new coalition dedicated to countering misinformation about ashwagandha leaf safety, defending GMP standards, and responding to what many in the industry see as scientifically unsupported regulatory actions: India’s April 2026 FSSAI/AYUSH leaf advisory and Denmark’s earlier ban.

(Read the article at PricePlow Blog here.)

In Episode #218 of the PricePlow Podcast, Mike and Ben sit down with Blake Ebersole, founding member of the ASA and president of NaturPro Scientific, a B2B quality and regulatory consulting firm. Blake unpacks and rejects the “root good, leaf bad” narrative, explains why in vitrocancer cell studies are being misused to target ashwagandha leaf, and details how lab shopping and supply chain fragmentation quietly erode quality across the botanical category.

View video on YouTube here: Ashwagandha TRUTH: Blake Ebersole on Labeling & India’s Leaf Ban | Episode 218

This episode pairs directly with our companion article on India’s ashwagandha leaf advisory. Together they cover both the regulatory deep-dive and the industry coalition response.

Blake Ebersole, founding member of the Ashwagandha Standards Alliance (ASA) and president of NaturPro Scientific, joins Mike and Ben to address the growing controversy around ashwagandha leaf safety: debating the “root good, leaf bad” narrative, India’s 2026 FSSAI/AYUSH advisory, Denmark’s hazard-based ban, and the withaferin A in vitro science being misused across the industry. The conversation goes far beyond regulatory news. The guys dig into:

• Lab shopping and the broken incentive structure in supplement testing
• Supply chain fragmentation in India and how it creates quality failures at scale
• Label disclosure: plant part, withanolide content, and maltodextrin dilution
• The difference between hazard-based and risk-based regulatory frameworks
• The ASA’s three founding executive members: Sabinsa, Cepham, and Arjuna Natural
• Formula ideas for the next wave of ashwagandha products (sleep, specific populations, acute stress)
• Anhedonia, cortisol, and what the science actually says about ashwagandha’s mood effects

Sign up for ashwagandha news alerts on PricePlow: https://www.priceplow.com/ashwagandha Follow Blake Ebersole on LinkedIn:   / blakeebersole  

Ashwagandha Standards Alliance: https://ashwagandhastandards.org

TIMESTAMPS: 0:00 – Introductions 2:45 – What Is the Ashwagandha Standards Alliance? 4:30 – How ASA Fits Alongside AHPA and Trade Organizations 6:15 – Educational, Policy, and Standards Goals 8:00 – Adverse Events at Scale and Ashwagandha’s Safety Record 11:15 – Denmark’s Ban and the Hazard-Based Regulatory Model 15:15 – Withaferin A and the In Vitro Extrapolation Problem 18:30 – How Competitive Interests Drove the Market Off Track 21:00 – Label Disclosure, Dilution, and Maltodextrin 25:00 – The Billion-Dollar Market and Supply Chain Fragmentation 30:00 – India’s Regulatory Framework: Food, Drug, and No Middle Ground 32:15 – Farmers, Brokers, and Unintended Consequences 38:00 – Research Gaps and the Clinical Literature 41:00 – Extraction Methods: Milk, Solvents, and Withanolide Chemistry 44:30 – Consumer Education and the Demand for Transparency 46:30 – Lab Shopping and the Broken Incentive Structure 52:45 – Branded Ingredients and GMP Supplier Qualification 55:15 – ASA Founding Members: Sabinsa, Cepham, and Arjuna Natural 58:00 – Formula Ideas: Sleep, Lifestyle, and Beyond the Basics 1:00:45 – Anhedonia, Cortisol, and What the Science Says

Key articles and resources:

• India’s Ashwagandha Leaf Advisory – What FSSAI Actually Said: https://blog.priceplow.com/industry-n…
• How to Read Ashwagandha Supplement Labels: https://blog.priceplow.com/guides/ash…
• Shoden and the Ashwagandha Evolution: https://blog.priceplow.com/supplement…
• Shoden-R: Arjuna Natural’s Root Extract: https://blog.priceplow.com/supplement…
• Episode #207 – Cortisol Awakening Response / Shoden Research: https://blog.priceplow.com/podcast/co…
• Episode #171 – Arjuna Natural and the Shoden Revolution: https://blog.priceplow.com/podcast/ar…

Thanks to Perfect Shaker for sponsoring the podcast: https://www.priceplow.com/perfect-shaker

Does your ingredient intel know how your ingredients are made?

Because a lot of platforms can tell you what’s available and trending. They can give you a possible match, what the studies say and what competitors are doing.

But we’re still left hanging with the biggest question:

Do you know enough about the ingredient, the supplier, and the documentation to trust what you’re buying?

That’s where Fearless Naturals USA is different.

——

Some platforms make ingredients easier to find and buy.

Others generate more options.

Some platforms help people move faster through ingredient selection, while others help to focus on market, trends, and white space.

Those are all forms of intelligence, but Fearless is built around a different problem.

Trust.

——

Trust isn’t gained from “here’s an ingredient listing and a few nice claims”, “here’s is a giant catalog, good luck,” or “AI says this ingredient looks promising.”

Real trust comes from being more deliberate and selective.

Real trust is only gained based on structure, experience and evidence.

That is why Fearless isn’t really a marketplace — but more of an exclusive sourcing club.

——

We’re building the first controlled-access environment for serious buyers and trusted suppliers.

Not every supplier gets in, and not every buyer gets full visibility on day one.

That’s not a weakness — that’s the intended model.

Because premium ingredient sourcing doesn’t work like a flea market.

The best suppliers aren’t throwing their name into an open directory.

And discerning buyers don’t want to waste more of their time.

So Fearless isn’t the biggest list of whoever wants to register.

(And AI ain’t picking our ingredients, ever.)

We’re a place where serious buyers can evaluate serious suppliers with better evidence, better gating, and better judgment.

—-

The ingredient world doesn’t suffer from a lack of mediocre information.

We suffer from a lack of trust on ingredient quality and integrity.

We’re not here to show everyone everything that a computer can generate. Quite the opposite.

We’re here to show the right people — the Fearless Power Buyers — the best ingredients from the best suppliers.

That makes Fearless Naturals USA the first real trust marketplace for natural ingredients.

——

Launch is just weeks away. Subscribe for early updates here: https://lnkd.in/ePtPu99q

May 3, 2026 — Did FDA fulfill its promise on radical transparency on infant formula in the widely promoted Operation Stork Speed?

FDA’s recent infant formula testing results are reassuring. But in my opinion, they’re incomplete.

The agency reports that it tested more than 300 infant formula samples and generated more than 120,000 data points across lead, mercury, cadmium, arsenic, pesticides, glyphosate, glufosinate, PFAS, and phthalates.

FDA says the overwhelming majority of products had undetectable or very low contaminant levels.

And no glyphosate, surely to the Secretary’s surprise.

That’s great, and kind of what I expected to see.

I don’t understand the rationale behind the study design, however.

Why were 318 pesticides tested, when formula ingredients aren’t considered sources of them?

Was BPA part of the pthalates tested? Did any testing include plastic baby bottle leaching data?

We don’t know.

We do know that infant formula containing cows milk ingredients can contain traces of veterinary antibiotics. Cleaning agents used in processing can contribute perchlorate. Acrylamide was part of prior discussions on infant formula. And does anyone remember melamine and its related nitrogen doping sources?

None of these appear to be included in the testing.

We know that infant formula can be a source of pathogens like Cronobacter and Salmonella — what caused the recent product recalls and shortages.

Why didn’t the study include common pathogens?

We don’t know.

——

Outside of study design, FDA’s communication still falls short of “radical transparency.”

No full report or raw data was provided.

A full report would include methods, detection limits, product and lab identifiers, quality-control data, and statistical treatment. Other than by reference to existing guidances, none of these were provided.

Without details, it’s hard to say that the public can independently evaluate the agency’s conclusions.

That does not mean FDA’s conclusions are wrong. It just means they are not fully verifiable based on what has been released so far.

——

FDA deserves credit for the testing and publishing the broad findings as a summary and fact sheet.

But if the promise was radical transparency, the next step is obvious: publish the full data package, and explain why key contaminants were omitted from the study.

Based on FDA’s summary, there does not appear to have been a broad contaminant crisis in U.S. infant formula, as previously stated by the guy running for President at the time.

There was a need for monitoring and better sharing of data.

But there may also have been a great deal of unnecessary fear.

We don’t know.

When the study design makes sense to food quality folks, and the results are provided as a complete package — maybe we can make a better conclusion then.

FDA Infant Formula Testing Results: https://www.fda.gov/food/infant-formula-homepage/fdas-infant-formula-product-testing-results

The truth will set us free.

Many are interpreting the AYUSH/FSSAI action differently than it actually is.

The Ashwagandha Standards Alliance, a robust, growing group of responsible firms, is addressing these and other related issues one by one.

Undeclared aerial-part substitution should be taken seriously. Yet ashwagandha ingredients from reputable suppliers already properly label plant part as part of GMP — so this looks like a bit of a red herring for other issues.

The action is also being interpreted as a regulatory restriction applying to countries outside India, when it is only a continuation of a misguided 2021 advisory and 2024 scientific reviews.

As a regulatory decision within India’s own traditional medicine and food framework, the ruling should not be misread anywhere else as a global scientific verdict that ashwagandha leaf is unsafe.

Overall, the action is misguided in a few ways.

First, the action conflates legitimate use of root and leaf with adulteration. “Adulteration” is a legal and regulatory definition and should not be thrown around casually.

The truth is, more than 30 clinical and safety trials have been conducted on properly labeled root+leaf products, showing an excellent record of safety and efficacy.

Second, the action neglects the body of evidence, recently compiled and published in Phytotherapy Research by Thomas Brendler and others, which shows an excellent record of safety for both root and leaf ashwagandha products.

Third, the action is based on a foundation of flawed, incomplete AYUSH-generated reports which omit a large amount of verified evidence, including the incorrect attribution of root-and-leaf evidence as root-only.

Fourth, the common argument that leaf was not used traditionally is incorrect. Tallon, Koturbash, and Blum’s 2025 systematic review in Phytotherapy Research catalogued leaf and aerial-part use across multiple traditional systems, including uses for fever, inflammation, wound poultices, and febrifuge applications in regional materia medica across India, Yemen, Ethiopia, Sudan, Jordan, the Sahel, South Asia, and other areas.

That does not mean all traditional leaf use automatically supports modern dietary supplement use — but that’s what we have scientific support for.

(When we have the science, how much of a difference does an already-incomplete historical record make?) Yet we are aware that any “no historical precedent” claim for leaf is incorrect and misguided.

The ashwagandha plot bubbles and thickens, and the crucible now precipitates visible impurity.

The Ashwagandha Standards Alliance applauds NutraIngredients for yesterday’s article by Asia Sherman, which illustrates all together the stark contrast between one popular narrative and the science.

The narrative says that root is authentic, that leaf is suspect, and that the Ministry of Ayush ban is a necessary correction.

But the science says something much different.

And to me, the real issue here is distraction without full disclosure — on multiple levels.

—–

First, we have those who drive the narrative, claiming that integrity is everything. If that’s so, then why is no one able to verify the composition of their products as they are labeled?

When a supplier states ‘root-only’, what does that really mean?

What are the individual compounds which comprise “total withanolides” printed on millions of product labels worldwide containing that ingredient?

If no one can answer these questions, then that’s the larger problem underneath, bubbling to the surface here.

—–

We also have those who are silently caught in a web. Like those whose science and safety was not on root-only material as previously disclosed — but actually on root+leaf.

This means much of the evidence previously thought root-only actually belongs in the root-and-leaf category.

It also means that consumption of root-and-leaf is much more widespread than previously thought.

And it means that literature used by the Ministry to generate its conclusions has been misclassified, while the misguided claim that root-and-leaf lacks sufficient evidence becomes much weaker.

How many clinicals and safety studies on root-and-leaf is good enough? Does 30+ sound like enough?

—–

Ultimately, whether leaf is added to root or not, the science suggests that the plant-part hullaballoo may be a red herring when it comes to safety.

Thanks to recent published reviews by Thomas Brendler and colleagues, the adverse-event record does not establish causality by either plant part.

And as Mark Blumenthal noted: properly labeled leaf-containing products are not adulterated simply because they contain leaf. As much as the “root-good-leaf-bad” folks would like us to think, there’s no evidence that the leaf is unsafe.

The picture outside of the crucible is actually simple and clear.

We need plant-part disclosure, better identity testing, validated analytical methods, adequately labeled products.

And all of that — not just the parts that people want us to see.

Because these are simple, basic GMP’s which no amount of influence will change.

Article link: https://www.nutraingredients.com/Article/2026/04/28/india-bans-ashwagandha-leaf-use-in-any-form-industry-reacts/

Posted by Supp.Co, April 22, 2026 — The supplement industry has a quality problem. Not a shortage of it. A definition problem. Every brand claims it. Almost none of them mean the same thing.

(Read the full article here.)

“Quality is like an onion with a thousand layers. By the time you get to the core, you’ve shed a few tears, because you’ve seen how things really work.”

I sat down with Blake Ebersole to talk about what quality actually means when you strip away the marketing. Blake has spent more than two decades on the back end of this industry: reviewing labels, qualifying ingredient suppliers, auditing manufacturers, and building the kind of specifications that most brands don’t know exist. What he described is a system so layered and so poorly understood by most people operating inside it that the word “quality” has become almost meaningless.

Here’s what I took away.

Quality Is a Checklist… a Very Long One

Blake doesn’t think in abstractions. He thinks in checkboxes.

Good Manufacturing Practices alone carry roughly 300 checkboxes mandated by FDA regulations. Label compliance adds another 100, down to the precise thickness of the lines in your Supplement Facts panel, which most companies get wrong because the regulation exists but isn’t commonly enforced. Ingredient specifications for botanicals can add 200 more. Supplier qualification: another 150.

By his count, a truly rigorous quality framework has around 1,000 checkboxes. A typical Amazon-seller brand checks maybe 50 of them. Not because they’re trying to cut corners, but often because they don’t know the other 950 exist.

Full video “How To Choose Supplements Like an Expert” here.

He breaks the industry into four tiers. Most brands fall into tier one or two: either well-intentioned but undereducated, or roughly FDA-compliant but missing the depth. Tier three is the established players who know what they’re doing but rely heavily on outside consultants and still have gaps. Tier four, the true one-percenters, are companies like Amway Nutrilite, who have full testing systems, institutional knowledge built over decades, and enough scale that a single screw-up becomes an existential risk.

Most of what you see on shelves is tier two.

Where Good Intentions Break Down

The supplement supply chain has at least three links before a finished product reaches you: ingredient supplier, possibly a distributor, then a contract manufacturer, then the brand whose name is on the label. At each handoff, quality requirements only flow as far as the knowledge of the buyer.

If a brand doesn’t know what a proper ingredient specification looks like, that gap travels all the way back to the raw material.

Blake’s most common citation from FDA audits and warning letters: specifications and identity testing. The issue with specifications isn’t usually what’s on them. It’s what’s missing. A short spec for green tea extract might look fine on its face. But if you don’t know what should be there, you don’t know what’s absent. Most brand owners aren’t green tea extract experts. Nobody can be an expert in every ingredient.

Identity testing has its own games. Some companies send the same sample to multiple labs and keep the result that passes. Others use their supplier’s test as their own verification without running it independently. There’s no system-level control against either practice.

Botanicals Are a Different Beast

Single-molecule ingredients, vitamin C and magnesium glycinate for example, are relatively straightforward to specify and test. Botanicals are not.

A botanical isn’t one molecule. It’s a mixture of tens of thousands of compounds. Blake’s analogy: you can manage one or two kids at home. Try being a principal managing a thousand who are fighting each other and going missing. That’s botanicals.

Specifications for a botanical ingredient are often three to four times longer than for a synthetic vitamin. You’re measuring marker compounds for potency, screening for adulterants, testing for pesticide residue, and trying to confirm identity in a matrix that can vary significantly between batches, farms, and seasons.

Adulteration in this category is common, but it’s not always malicious. The most frequent form is economically motivated dilution: adding starch or maltodextrin to an extract to pad volume and margin. Starch is actually quite difficult to detect chemically, which is part of why it’s so commonly used. The consumer ends up with a product that looks right on the label but doesn’t deliver the potency they’re paying for.

The worst adulteration isn’t the deceptive kind. It’s the accidental kind. An undeclared allergen from a labeling error. That can kill someone.

What Can Go Wrong in Manufacturing

Even when a brand starts with high-quality raw materials, problems can emerge at every stage of production. Blake broke it down clearly:

• Farm level: Drying and milling often happen at separate facilities, meaning the ingredient changes hands before it ever reaches a manufacturer. Salmonella and other pathogens can be introduced here, and insufficient processing later won’t catch them.
• Shipping and storage: Raw materials are sometimes transported overseas between processing steps. Temperature, humidity, and handling during transit can all degrade quality in ways that aren’t visible in a finished product test.
• Contract manufacturing: Most brands don’t manufacture their own products. Their contract manufacturer has 200 other customers. The brand assumes their standards are being applied, often without any verification mechanism in place.
• Final testing: A manufacturer can test a batch, get a negative result for pathogens, and still ship a product that causes illness. That’s not a system failure. It’s the nature of sampling in large-volume production. One drum can test clean while the one next to it is contaminated.

When something goes wrong, the FDA warning letter goes to the brand, not the manufacturer. The brand’s name is on the label. That association lives in the public record indefinitely.

The Processing Paradox

There’s a widely held belief in wellness culture that less processing is always better. Blake pushes back on this hard.

Processing exists, first and foremost, to make things safe. Cooking, drying, acidifying, milling: these aren’t modern interventions. Humans have been dehydrating and grinding botanicals for 40,000 to 50,000 years.

His clearest example: greens powders. Consumers want a vibrant green product because green signals “fresh” and minimally processed. 

But chlorophyll is unstable; heat degrades it. So manufacturers under-process to preserve color, and in doing so they sacrifice food safety. Salmonella can be present in raw greens at the farm level, sometimes as an endophyte living inside the seed itself. Insufficient heat doesn’t kill it. A bright green greens powder is actually a prompt to look more closely at that brand’s food safety protocols, not a reassurance.

Third-Party Testing Is Not a Gold Standard

“Third-party tested” has become the default quality signal for consumers and retailers. Blake respects the concept. He has serious concerns about how it plays out in practice.

Labs are businesses. They compete on price. An HPLC test for $50, a price point he’s seen in cannabis testing, is not running the controls between runs that ensure the equipment is working correctly. Someone on the brand or manufacturer side has to actually understand what good testing looks like to evaluate whether they’re getting it.

ISO 17025 certification, now required by Amazon, is a step up. But it only covers validated methods at that lab, and many labs don’t validate their methods for the specific product matrix they’re testing. Turmeric is antimicrobial. If the test doesn’t account for that, the turmeric can suppress the pathogen in the sample and the product registers as clean even when it isn’t.

His rule: the lab report should state not just that the lab is ISO certified, but that the specific method used is ISO certified. That’s a much shorter list.

What You Can Actually Do

Blake’s practical framework for consumers:

• Learn what a compliant label looks like. Use an established brand like NOW Foods as a reference. If a label looks different in structure or formatting, that’s worth a closer look.
• Buy from large, established brands. Companies that have survived FDA scrutiny and built institutional knowledge over decades are operating differently than a two-year-old brand.
• Price signals matter. A $20 multivitamin is almost certainly cutting somewhere. Compare cost per capsule at equivalent dosages. In this industry, there are no real deals.
• Watch the claims. Vague mechanism-of-action language is often a sign that there’s no clinical evidence behind the product. Companies lean on it because it’s harder to enforce.
• Invest time proportional to what you’re investing in. If you spend ten hours a week on fitness, spending five minutes picking a supplement is a mismatch.

Watch the full conversation with Blake above for more on the supply chain opacity problem, what a proper ingredient specification actually looks like, and his take on the botanical formulation he helped develop that he thinks deserves more attention.

Back before I knew any better, I thought natural products were easy.

I used to think sourcing was easy.

Find a supplier online. Get a spec sheet. Allergen statement, SDS. Done.

Then you learn that “same ingredient” can mean different countries, different processing, different adulteration risks, different documentation, different actual quality.



I used to think testing was easy.

Send it to a lab. Get a number. Problem solved.

Then you learn the method might not fit the ingredient. The sample might not represent the lot. The result might look scientific and tell you almost nothing useful.

That’s before you test out-of-spec for a $50,000 batch of material that everyone else is dying to accept on deviation.

——

I used to think labels were easy.

Just say what it is, what it does and move on.

Then you learn how many products are built backwards — marketing first, evidence later, labels last. Fancy claims with weak support.

And a whole lot of crossed fingers riding on the label review.

——

I used to think GMPs were easy.

Follow the rules. Check the boxes. Keep going.

Then you learn that minimum compliance and actual quality are not the same thing. A check-box is left to interpretation, and a lot of people can survive the thin cross-section of an audit.

Seldom are systems built and maintained that consistently prevent problems.

——

I used to think product success was easy.

Good ingredient. Good packaging. Good story. Launch it.

Then you see a thousand similar products on Amazon. You walk the closeout aisle and see the markdown graveyard. Or the dusty tops of near-expired units.

All filled with big promises that no one cared about.

——

A lot of things look easy from far away.

Especially in supplements, food and cosmetics.

But the longer you do this, the more respect you gain for the boring parts. The questions, the methods, the documentation.

And especially the judgment and the restraint.

Without that respect and that experience, it’s easy to call failure a surprise.

Once upon a time, I was fresh.

Today, I wish I had SupplySide Fresh — an industry onboarding program for new hires and newcomers to the health and nutrition industry. Learn from me and other experts, build valuable connections and accelerate growth in this dynamic field.

Why choose SupplySide Fresh?

Comprehensive education

Learn from industry experts through curated sessions covering key topics, including trends, regulations and important partnerships.

Networking and community building

Networking and community building: Build meaningful connections with peers, mentors and industry leaders, both online and in person.

Tailored for newcomers

Whether you’re starting a new career or transitioning into a new role, SupplySide Fresh will help you navigate the industry’s complexities and accelerate your success.

SupplySide Fresh is designed to help newcomers — and professionals stepping into new roles — get up to speed quickly in the nutrition industry. The program combines online education, practical industry context, and virtual and in-person networking to help participants understand how the industry works, who the key players are, and what knowledge is needed to contribute with confidence.

The program offers two course tracks: Food & Beverage and Supplements. Each track is built around curated educational modules covering industry resources, business operations, supply chains, due diligence, legal and regulatory basics, trends, partnerships, and networking. The supplement course includes topics such as adulteration risk, clinical trials, supplement quality, GMPs, labeling and claims, GRAS vs. NDI, and DSHEA history.

For companies, SupplySide Fresh can serve as a structured onboarding tool for new hires, helping reduce ramp-up time and provide consistent baseline training across teams. For individuals, it offers a practical entry point into a complex industry, with on-demand learning, optional quizzes, networking opportunities, and a certificate of completion co-branded with Sonoran University of Health Sciences.

The value of SupplySide Fresh is that it does not treat the nutrition industry as a simple product category. It recognizes that success in supplements, functional foods, beverages, and ingredients requires understanding regulation, quality, science, manufacturing, marketing, trade media, testing, claims, supply chains, and relationships. In other words, it is not just a course. It is an industry orientation.

For anyone entering the nutrition industry — whether through sales, marketing, quality, regulatory, R&D, operations, investment, entrepreneurship, or brand leadership — SupplySide Fresh provides a practical foundation for learning the language, avoiding common blind spots, and building the relationships needed to grow.

https://supplysidefresh.com/

hashtag#supplysidefresh hashtag#healthandnutrition hashtag#industryeducation hashtag#professionalnetworking

Linear thinking is often our default model of thought. But it’s not reality.

In a supplement formulation meeting many years ago, I suggested to a top supplement brand that cyclical dosing for a certain ingredient would follow the science and might be prudent.

They paused. Looked at me, then at each other. And they changed the subject.

Without a word, I learned in an instant that the nutrition business is much different than the nutrition science.



Today, still, wellness solutions are sold with a childish assumption: if some is good, more must be better.

More sun, heat, cold. More magnesium and vitamin D. More water and electrolytes.

On the flip side, if less is good, zero must be great.

Zero sugar. Zero carb. Free from (fill in the blank: _________)

But linear thinking fails for many reasons. Here’s why…

——

First, biology rarely works in straight lines. Too little can hurt you. Enough can help you. Too much can hurt you again. It’s not a straight diagonal line — the outcome as the input increases is parabolic, or some other type of curve.

Second, we are almost never dealing with one variable at a time. We are dealing with many.

More water affects sodium balance. More sodium creates a potassium imbalance. Then we need more water again.

More sun past a certain small amount saturates vitamin D production, while increasing UV exposure and skin cancer risk.

Lower carb intake may help lower blood glucose, but increase fat intake or worsen fiber intake or training output.

More sauna or cold exposure may help at one dose, but reach diminishing returns while piling onto the stresses of everyday life.

That’s what bad health advice leaves out. It treats one input like a lone hero.

Or worse — ‘stacks’ them to no benefit.

—-

Let’s take an example — that ‘everyone’ should supplement magnesium.

There’s some truth in that claim. Magnesium is essential, and some people don’t get enough and benefit from supplementing it.

But that’s not the same as saying everyone needs to take a well-absorbed form of magnesium every day.

And this is where science and sales split.

The science question is: Who actually needs magnesium, in what form, at what dose, for what reason, and for how long?

While the sales question is: How do we turn magnesium into a daily habit for as many people as possible?

—-

Linear thinking for supplements is profitable. Take it every day and keep going, and don’t ever cancel your subscription, because, well… profit margins.

But the science says: The dose-response for magnesium is not a straight line. Magnesium is not a drug. We’re already getting some from our food. Feedback inhibition maintains equilibrium — that’s the ‘expensive pee’ argument.

So the science says cycling or skipping a day or a week occasionally make more sense than the daily status quo.

Yet as many of us are aware, what’s good for science is often bad for business.

This gap in between explains much of where the health and wellness industry misses our mark.